Background
==========

The ABO blood group system is the most clinically significant system in transfusion and transplantation medicine. The *A*and *B*genes are co-dominant, so individuals can be phenotyped as A, B, AB or O. A common dimorphism in some populations leads to the division of blood group A into A~1~and A~2~, the latter showing weaker antigenicity. On occasion, A~2~activity is weakened further when competition due to a co-dominant *B*gene occurs (A~2~B phenotype).

*ABO*allele nomenclature poses significant problems that are still under consideration by the International Society of Blood Transfusion (ISBT). In the absence of an officially agreed terminology, alleles are referred to here by their serological activity and an alternative allele name^1^is given in square brackets.

The *ABO*gene contains seven exons and a 1062 base pair (bp) sequence codes for a glycosyltransferase, of which the *A*^1^\[A101\] allele (usually described as the consensus allele) product adds a monosaccharide (*N*-acetyl-α-D-galactosamine) to a specific acceptor glycoconjugate. The *B*\[B101\] allele produces a similar protein, differing only in four amino acids, but these changes result in a modified enzyme specificity \[[@B2]\]. The same acceptor glycoconjugate is utilised, but the B-specific monosaccharide, α-D-galactose, is added (for a review, see \[[@B3]\]). The coding region of the *A*^2^\[A201\] allele differs from *A*^1^by a seemingly innocuous 467C\>T (Pro156Leu) substitution and a 1061delC that causes a frame-shift and extends the reading frame by 64 nucleotides \[[@B4]\]. Many other mutations have been described \[[@B5]\] that weaken these activities and result in weak A or B subgroups. Totally inactivating mutations result in the blood group O phenotype, the most common of which is a deletion at nucleotide (nt.) 261 (261delG) in exon 6 that results in a frame-shift and premature termination of translation \[[@B2]\]. Two major alleles of this type exist. The first allele (*O*^1^\[O01\]) differs from the consensus *A*\[A101\] allele in all seven exons by only this mutation. The second allele (*O*^1*v*^\[O02\]) \[[@B6],[@B7]\] has nine further mutations spread across exons 3--7 in addition to 261delG and an additional 13 mutations have been found amongst the 1052 nucleotides in intron 6 \[[@B8],[@B9]\].

Other alleles have been described that are predicted to lead to amino acid substitutions or frame-shifts \[[@B5]\], or alternative splicing \[[@B10],[@B11]\] and a dimorphic enhancer region has been reported \[[@B12]-[@B14]\]. Several alleles at the *ABO*locus appear to arise by crossing over between two dissimilar alleles. First described in 1996 \[[@B15]\], a *B*allele was continued as an *O*^1*v*^allele from downstream of the middle of the last and largest exon (exon 7). The B-enzyme-determining mutations occur after the cross-over point and the *O*^1*v*^sequence after this point only differs from the consensus (*A*^1^) sequence by two point mutations, of which only one would lead to an amino acid change (Val277Met). This change presumably weakened the A enzyme activity, as the resulting phenotype was A~2~, albeit from a *B-O^1v^* hybrid allele \[A204\]. Other examples on the same theme include several *A*^*x*^alleles based on the 5\'-ends of *A*or *B*alleles in combination with the 3\'-end of the *O*^1*v*^allele \[[@B9],[@B16]\]. However, many of the hybrid alleles described so far are hybrids of *O*^1^and *O*^1*v*^, have 261delG, and hence are *O*(i.e. inactive) alleles \[[@B17]\].

We describe here a new hybrid *A*allele having *O*^1*v*^-*A*^2^allele characteristics in five individuals of A~weak~B phenotype from different parts of the world, but having a common ethnic background. This is the first allele described in which the effect on enzyme activity of the mutations in the *O*^1*v*^allele prior to exon 6 can be shown.

Results
=======

Blood group serology
--------------------

The five individuals from Portugal (origin: Guinea Bissau), Sweden (n = 2, origins: Senegal and Zimbabwe), Switzerland (origin: the Dominican Republic), and the USA were all Black and of African or Afro-American descent. On routine typing they were found to express the A antigen weakly on their red blood cells (RBC) whilst the B antigen was expressed normally. Fresh blood samples from all five subjects were subjected to an extended serological analysis at the referring transfusion centres. Three of the samples were analysed with a panel of commercially available polyclonal and monoclonal anti-A reagents (described previously in \[[@B18]\]) for further characterisation of the weak A phenotype. One monoclonal reagent (Seraclone) agglutinated the RBC almost completely (3+ reaction with few unagglutinated cells) but the other reagents gave mixed field reactions (macroscopic reading ranging from negative to 1+/2+). All reactions were also read microscopically and weak agglutination with mixed field was verified also in the reagents yielding macroscopically negative readings. Adsorption of red cells with anti-A and subsequent elution yielded an eluate containing anti-A (only performed in one case). Anti-A~1~was present in serum from all subjects but one also had a weak anti-A reactive only after incubation at 4°C. Saliva testing was not performed due to lack of saliva samples and/or non-secretor status as judged by Lewis blood group phenotyping.

Blood samples from the parents of the Portuguese individual were also investigated. Whilst the father had the common B phenotype, the phenotype of the mother was A~weak~but with a strength of reactions suggesting an intermediate form of A antigen expression, weaker than A~2~but stronger than the one observed in the A~weak~B cases studied here.

Blood group genotyping
----------------------

All samples were found on initial genotype screening \[[@B19]\] to have the *A*^2^*B*genotype and lacked the majority of previously reported mutations associated with weak A or B expression \[[@B16],[@B20]\]. Further analysis by *A*^2^-specific PCR-ASP \[[@B18]\] established the presence of the 1061delC mutation \[[@B4]\] and *B*-specific PCR-ASP \[[@B16]\] indicated the presence of a normal *B*allele \[[@B21]\]. In addition, enhancer mini-satellite PCR analysis indicated that four of these samples were homozygous for four 43 bp-repeats in the CBF-NF/Y-binding domain approximately 4 kbp upstream from the translation start codon, as expected \[[@B13]\]. Interestingly, the individual originating from the Dominican Republic was heterozygous for one and four repeats, thus deviating from the rule \[[@B13]\].

A *BstU*I-based PCR-RFLP test \[[@B7]\] results in cleavage between 188C and 189G in exon 4 of all known alleles except *O*^1*v*^(and some minor variants of *O*^1^and *O*^1*v*^\[[@B5]\]), which has two mutations at these positions (188G\>A and 189C\>T). The indication that these five individuals already genotyped as *A*^2^*B*were also heterozygous for an *O*^1*v*^allele-specific mutation led us to sequence exons 1--7 to investigate the reason for this anomaly.

Based on information obtained about the geographic and ethnic origin of the individuals with the anomalous *A*allele, we also performed genomic typing of the *FY*and *RHD*blood group loci according to published methods \[[@B22],[@B23]\]. The silent *Fy*allele (based on the *Fy*^*b*^sequence with a disrupted GATA-1-binding motif in the promoter region \[[@B24]\]) commonly found in individuals of Black ethnic origin but not in Caucasians was detected in the homozygous or heterozygous state in all five cases whilst the *RHD*pseudogene \[[@B23]\] exclusively found in some Blacks was detected in the Portuguese sample only.

DNA was also isolated from blood from the parents of the Portuguese A~weak~B individual. The mother was genotyped as *A*^2^*O*^1*v*^and the father as *BO*^1^. Further investigation of the mother\'s *A*^2^-like allele showed the same hybrid allele as her son and the other four index cases, as expected.

*ABO*exon sequences
-------------------

The complete coding region (all seven exons, comprising 1128 bp) of the *A*^2^allele was sequenced in all five samples.

The nucleotide sequence in exons 6 and 7 was identical to the non-Asian *A*^1^consensus allele except for the characteristic mutations (467C\>T and 1061delC in exon 7) found in the common *A*^2^allele.

The sequences in exons 1--5 were similar to the consensus allele, except for 106G\>T (exon 3), 188G\>A (exon 4) and 220C\>T (exon 5), all consistent with the presence of an *O*^1*v*^allele. Surprisingly, the *O*^1*v*^-specific mutation, 189C\>T, was absent, whereas a hitherto undescribed mutation in exon 2 (46G\>A) was found in all five samples. As opposed to the situation in *O*^1*v*^, the effect of these missense mutations can be seen in the translated transferase, as the *O*^1^/*O*^1*v*^-specific 261delG mutation is not present in this allele. The amino acids predicted to occur as well as their relative locations in the translated protein are shown in Figure [1](#F1){ref-type="fig"}.

![Depiction of the relative locations of amino acid substitutions caused by the novel allele. A schematic representation of the A transferase resulting from transcription and translation of the novel allele is shown on the left side whilst a computed 3D-model on black background is displayed on the right side. In the former, all amino acid substitutions resulting from the four missense mutations in the *O*^1*v*^*-A*^2^hybrid are shown as coloured circles highlighted by dotted arrows. In the latter, only two of the mutated positions could be displayed in the model since the two N-terminal substitutions were not included in the expressed soluble portion of the crystallized A transferase \[[@B32]\] on which the template structure (molecular coordinate file 1LZ0 in the NCBI structure database) was based. The 3D surface model was created with the DeepView Swiss Pdb Viewer version 3.7, an interactive molecular graphics programme for viewing and analyzing protein structure (<http://www.expasy.org/spdbv> and \[[@B33]\]) using the molecular surface mode and the 3D rendering display option. No effort was made to calculate the possible structural alterations caused by the amino acid changes. The original sequence expressed for the crystallographic study \[[@B32]\] was used for the analysis. Residue positions 63 and 74 are highlighted in red and green, respectively, to show their relative locations in the model. In addition, the DXD motif (present in almost all glycosyltransferases, here as DVD capable of binding the UDP part of the nucleotide-sugar substrate) is shown in blue in order to highlight the catalytic cleft. The different regions of the glycosyltransferase are shown according to Paulson and Colley \[[@B34]\] and the transmembrane domain (amino acids 17--37) is based on the hydrophobicity plot and amino acid composition originally reported by Yamamoto et al. \[[@B35]\]. The black X represents the approximate location of a proteolytic cleavage site for generation of the soluble glycosyltransferase found in body fluids.](1471-2156-4-17-1){#F1}

A possible hybrid allele breakpoint was suspected somewhere between the end of exon 5 and the beginning of exon 6. We therefore sequenced the intervening intron 5 (see below) in an attempt to localise the cross-over region.

None of the more than 100 samples screened by PCR-ASP (i.e. at least 200 alleles, comprising over 50 *O*^1^and *O*^1*v*^alleles and at least 10 *A*^1^, *A*^2^, *B*, *O*^2^and *O*hybrid alleles, as well as several weak *A*alleles) had the new mutation, 46G\>A (Ala16Thr). Amongst all these samples one *O*^1^allele from a Jordanian individual was found to have the *O*^1*v*^-characteristic 188G\>A (Arg63His) mutation. One *O*^1*v*^allele from an African individual lacked the *O*^1*v*^-characteristic 189C\>T (silent) mutation.

*ABO*intron sequences
---------------------

### Intron 5

Intron 5 from a number of individuals with the common alleles, *A*^1^(two homozygotes), *A*^2^(two homozygotes), *B*(one homozygote, one heterozygote), *O*^1^(two homozygotes), *O*^1*v*^(two homozygotes),*O*^2^\[O03\] (three heterozygotes) and the new suspected hybrid alleles was sequenced. Three *A*^2^and three *O*^1*v*^alleles from Black African donors were also sequenced for comparison. Eight polymorphic nucleotide positions were found in the 554 bp sequence and these are shown in Table [1](#T1){ref-type="table"}. Intron 5 sequences in the Black African samples were identical to the respective alleles of the other (Caucasian) control material. The sequence in the new allele was consistent with a crossover between an *O*^1*v*^and an *A*^2^allele after nt. 103insCCC but before 306C in intron 5. This is shown schematically in Figure [2](#F2){ref-type="fig"}.

###### 

Polymorphic nucleotide positions in introns 2--5 of the *ABO*gene.

               **Intron 2 (724 bp) nt. position**                                                                                                                                                                       
  ------------ ------------------------------------- ------------- ----------- --------- --------- --------- --------- ----------- ----------- ----------- --------- --------- --------- --------- --------- ---------- ---------
  dbSNP rs                                                         2073828     2073827   687289    687621    2073826                                                                                                    
                                                                                                                                                                                                                        
  *A*^1^       A                                     C             C           C         T         C         C                                                                                                          
  *A*^2^       A                                     C             C           C         T         C         C                                                                                                          
  *B*          A                                     C             C           C         T         C         C                                                                                                          
  *O*^1^       A                                     C             ***T***     ***G***   ***C***   ***T***   ***A***                                                                                                    
  *O*^2^       A***A***                              C/***T*\***   ***T***     ***G***   ***C***   ***T***   ***A***                                                                                                    
  *O*^1*v*^    A                                     C             C           C         ***C***   ***T***   C                                                                                                          
  new hybrid   A                                     C             C           C         ***C***   ***T***   C                                                                                                          
                                                                                                                                                                                                                        
               **Intron 3 (1451 bp) nt. position**                                                                                                                                                                      
  **Allele**   205                                   354           399         479       525       575       969       1063        1095        1096        1170      1244      1278      1357                           
                                                                                                                                                                                                                        
  dbSNP rs     493211                                              8176701     579622    579483    8176702   575259    574347                              8176704   613423    551322    624601                         
                                                                                                                                                                                                                        
  *A*^1^       C                                     G             G           C         A         C         T         A           C           A           C         C         T         C                              
  *A*^2^       C                                     G             G           C         A         C         T         A           C           A           ***T***   C         T         C                              
  *B*          C                                     G             G           C         A         C         T         A           C           A           C         C         T         C                              
  *O*^1^       C                                     G             G           C         A         ***T***   T         A           C           A           C         C         T         C                              
  *O*^2^       C                                     G             G           C         A         C         T         A           ***del***   ***del***   C         C         T         C                              
  *O*^1*v*^    ***T***                               G             G           ***T***   ***T***   C         ***C***   ***G***     C           A           C         ***T***   ***C***   ***T***                        
  new hybrid   C                                     ***A***       ***A***     ***T***   ***T***   C         ***C***   ***G***     C           A           C         ***T***   ***C***   ***T***                        
                                                                                                                                                                                                                        
               **Intron 4 (1686 bp) nt. position**                                                                                                                                                                      
  **Allele**   28                                    73            102         114       163       215       216       346         375         738         1092      1176      1467      1496      1511      1623       1678
                                                                                                                                                                                                                        
  dbSNP rs     7848145                               6151203       8176707     625593    8176708   547495    626035    626792                  638756                517414    514708    641943    641959    8176712    4962040
                                                                                                                                                                                                                        
  *A*^1^       G                                     C             C           C         G         A         A         T           C           T           C         C         G         T         T         C          T
  *A*^2^       G                                     C             C           C         G         A         A         T           C           T           C         C         G         T         T         C          T
  *B*          G                                     C             C           C         G         A         A         T           C           T           C         C         G         T         T         C          T
  *O*^1^       G                                     C             C/***A***   C         G         A         A         T           C           T           C         C         G         T         T         C          ***C***
  *O*^2^       G                                     C             C           C         G         A         A         T           ***T***     T           ***T***   C         ***A***   ***G***   ***G***   C          T
  *O*^1*v*^    ***C***                               \*\*          C           ***T***   ***A***   ***G***   ***C***   ***G***     C           ***G***     C         ***T***   ***A***   ***G***   ***G***   C***C***   T
  new hybrid   ***C***                               \*\*          C           ***T***   ***A***   ***G***   ***C***   ***G***     C           ***G***     C         ***T***   ***A***   ***G***   ***G***   C***C***   T
                                                                                                                                                                                                                        
               **Intron 5 (554 bp) nt. position**                                                                                                                                                                       
  **Allele**   91                                    103           266         306       336       450       527       530                                                                                              
                                                                                                                                                                                                                        
  dbSNP rs                                           8176713                   8176714   8176715   8176717   8176718                                                                                                    
                                                                                                                                                                                                                        
  *A*^1^       T                                     C             G           C         G         C         G         A                                                                                                
  *A*^2^       T                                     C             G           C         G         C         G         A                                                                                                
  *B*          T                                     C             G           C         G         C         G         A**/*G***                                                                                        
  *O*^1^       T                                     C             G           C         ***A***   C         G         A                                                                                                
  *O*^2^       ***C***                               C***CCC***    ***A***     C         G         C         G         A                                                                                                
  *O*^1*v*^    T                                     C***CCC***    G           ***T***   G         ***A***   ***A***   A                                                                                                
  new hybrid   T                                     C***CCC***    G           C         G         C         G         A                                                                                                

\* C/T etc. indicates dimorphism at this position in the same allele from different individuals. \*\* Insertion of GTGTGGACAGAAG between nt. 72C and 73C of the consensus (*A*^1^\[A101\]) sequence in intron 4. Deviations from the consensus sequence are highlighted (bold italics).

![Representation of the exons and introns in *A*^2^and *O*^1*v*^alleles and the new hybrid allele. Exons are represented as thick boxes and introns as thin boxes. They are drawn approximately to scale except for the approx 13 kbp long intron 1. Filled regions indicate an *A*^2^sequence and unfilled regions an *O*^1*v*^sequence. The hatched region in the hybrid allele indicates the cross-over region. The grey area is presumed to have an *O*^1*v*^allele sequence, but lack of known mutations in exons 1 and 2 and the unsequenced intron 1 does not allow proof of this. The asterisks indicate the localisation of the four missense mutations compared to the common *A*^2^allele.](1471-2156-4-17-2){#F2}

### Introns 2, 3 and 4

Since the new allele has a novel mutation in exon 2 (46G\>A) and an unexpected lack of the *O*^1*v*^-specific mutation in exon 4 (189C\>T), other introns in the *A*^2^-like allele of the five A~weak~B samples were also sequenced and all gave identical results. Samples from the same 13 Caucasian and three Black individuals examined for intron 5 above were also analysed (Table [1](#T1){ref-type="table"}). Intron 1 was not examined due to its size (approx. 13,000 bp). We found 7, 12 and 17 polymorphic sites (point mutations, deletions and insertions) in introns 2, 3 and 4, respectively, in the common alleles (Table [1](#T1){ref-type="table"}).

The intron 2--4 sequences of the novel allele were identical to the *O*^1*v*^alleles sequenced except for three adjacent mutations in intron 3. The first, 205T\>C, caused a reversion to the consensus from *O*^1*v*^-specific, whereas 354G\>A and 399G\>A were mutations not previously encountered in any allele. Intron 3 in the *O*^1*v*^alleles from the control donors of African origin was sequenced and in each case was identical to Caucasian *O*^1*v*^alleles.

### Intron 6

Allele-specific variations in intron 6 have already been described \[[@B8],[@B9]\]. Four new mutations were found in the new hybrid allele when compared to the *A*consensus sequence (277A\>G, 286C\>T, 911G\>T and 952A\>G). However, intron 6 in three normal *A*^2^alleles from Black Africans with the common A^2^phenotype also had these mutations.

Discussion
==========

Detailed analysis of the alleles at the blood group ABO locus is shedding light on the effect of polymorphism in different regions of the translated products, the blood group A and B glycosyltransferases, and ultimately the clinically important ABO phenotype of red cells. Factors with the potential to influence the glycosyltransferase activities include base insertions, deletions and substitutions mainly in exons 6 and 7 (for review see \[[@B5],[@B25]\]), hybrid alleles \[[@B17]\], splice-site mutations \[[@B10],[@B11]\], variations in enhancer activity \[[@B12]-[@B14]\], promoter methylation \[[@B26]\], promoter mutations \[[@B27]\] and alternative promoter regions \[[@B28]\].

The new allele described here is unusual in several respects. The *O*^1*v*^-characteristic mutations, 106C\>T, 188G\>A and 220C\>T in exons 3, 4 and 5, respectively, in combination with the common *A*^2^-specific sequence in exon 7 suggested that the allele is an *O*^1*v*^*-A*^2^\[O02-A201\] hybrid having a crossing-over point after nt. 220 in exon 5 and before nt. 261 in exon 6. A deletion at nt. 261 is the most common inactivating event creating *O*alleles and is present in both *O*^1^and *O*^1*v*^alleles and hybrid variants of these as shown in Figure [3](#F3){ref-type="fig"}. This mutation is absent from the five hybrid alleles described here and hence the cross-over should occur upstream of this position. In an attempt to determine the cross-over point more precisely and confirm the identity of the two contributing alleles we sequenced the intervening intron (intron 5) in the hope that allele-specific mutations were present in this intron, by analogy with our previous findings in intron 6 \[[@B9]\]. As Table [1](#T1){ref-type="table"} shows, eight of the 554 nucleotides in the intron were polymorphic. In this intron the *A*^1^, *A*^2^, *B*and *O*^1^alleles are very similar, differing only at nt. 336 in the *O*^1^allele and at nt. 529 in only one of the three *B*alleles tested. More pronounced differences were observed in the *O*^2^alleles that differed at each of the first three polymorphic positions (the complex variations in the *O*^2^allele will be presented elsewhere), and in the *O*^1*v*^alleles, that differed at four of these sites. This latter information allowed us to determine the crossing-over point to occur in intron 5 between nt. 103 and 306, and that the allele is indeed an *O*^1*v*^*-A*^2^hybrid (Figure [2](#F2){ref-type="fig"}).

![Known hybrid alleles at the *ABO*locus. The common alleles are also shown for comparison. Only changes from the consensus (*A*^1^*-1*) sequence are shown. Mutations causing amino acid changes are shown in bold face. The yellow areas indicate a reading frame shift. The blue areas indicate untranslated regions. The introns are represented by the thick, dark vertical bars. The blue rectangles indicate the region of the allele where a crossing over event occurred. ?, indicates that the nucleotide at this position was not described.](1471-2156-4-17-3){#F3}

This new allele showed some additional interesting characteristics. The mutation, nt. 46G\>A (Ala16Thr) in exon 2, has not been described in any other context, nor could we detect this mutation when we analysed 260 alleles from individuals of diverse ethnic background (of whom about 40 were African). Its occurrence in all five index samples, albeit from individuals of Black African descent, collected from diverse parts of the world is surprising.

Few mutations have been found in exon 4. Both 188G\>A and 189C\>T have hitherto been exclusive characteristics of the *O*^1*v*^allele; 190 G\>A has only been found in some Brazilian Black *O*^1^alleles \[[@B29]\]; and 203G\>C occurred in some Scandinavian *A*^*weak*^alleles \[[@B16]\]. The finding of 188G\>A without 189C\>T in the new allele was also unexpected. When we screened more than 200 alleles at these positions we found one otherwise normal *O*^1*v*^allele (African) having 188G\>A but lacking 189C\>T and one otherwise normal *O*^1^allele (Jordanian) having 188G\>A. Although infrequent, additional genetic diversity obviously exists in individuals with common ABO phenotypes.

Several hybrid alleles at the *ABO*locus have been reported previously (reviewed in \[[@B17]\] and summarised in Figure [3](#F3){ref-type="fig"}). About half of these alleles are *O*alleles containing the common inactivating deletion at nt. 261 contributed by the *O*^1^or *O*^1*v*^part of the hybrid. The others described so far are *A*alleles of varying activity, containing initial *A*or *B*sequences followed by *O*^1^or *O*^1*v*^sequences, where the critical nt. 261 is supplied by the *A*or *B*allele and is thus not deleted. The decreased A antigen expression is attributed to mutations in exon 7 (which encodes the enzyme\'s active site) contributed by the *O*^1*v*^allele. This novel *A*^*weak*^allele described here is the first example of a \"reverse\" hybrid, where the weakening of enzyme activity from A~2~to A~weak~may be due to the concerted effect of the mutations in exon 2 at 46G\>A (Ala16Thr), exon 3 at 106G\>T (Val36Phe), exon 4 at 188G\>A (Arg63His) and exon 5 at 220C\>T (Pro74Ser). However, theoretically the A~weak~phenotype may depend on only one or a combination of some of these four mutations.

Based on the linear structure, the former two substitutions presumably occur in or near the predicted transmembrane domain whilst the latter two localise to the postulated stem region of the Golgi-membrane-anchored enzyme. None of them is thought to occur in the proximity of the active site, which would be expected to have the normal A~2~enzyme structure based on the sequence of exon 7. In order to visualize this prediction, we created a three-dimensional computer model of the A transferase for mapping of two of the mutated amino acid positions onto the crystal-structure-based molecular surface. The result appears to confirm that residues 63 and 74 are localised far from the enzymatically active site in a stalk-like part of the protein (Figure [1](#F1){ref-type="fig"}). It should be emphasized that we did not attempt to determine the effect that these mutations would have on enzymatic function or fine structure of the gene product. Expression studies beyond the scope of this study or the future finding of other samples carrying other combinations of the above mutations may be able to address this issue.

The mutations found early on in intron 3 of this new hybrid allele (the consensus 205C rather than the *O*^1*v*^-specific 205C\>T, as well as the unique 354G\>A and 399G\>A) appear to be a specific characteristic of this new allele since intron 3 of the three control *O*^1*v*^alleles from Black African individuals did not differ from Caucasian samples. On the other hand, the four new mutations found in intron 6 of the new hybrid allele were also found in the three Black African *A*^2^alleles, which led us to conclude that the alterations observed in intron 6 may simply reflect a common ancestral *A*^2^allele of African evolutionary lineage.

The A and B glycosyltransferases compete for the same acceptor glycoconjugates. However, the weaker A activity due to this new allele was also observed serologically, although to a lesser degree, in the mother of one of these A~weak~B individuals who had inherited the hybrid allele in combination with an *O*allele and hence lacked a *B*gene. This may indeed be the reason why all five index samples studied here were A~weak~B. Obviously, the weakening effect of this hybrid is relatively mild so that the A~weak~phenotype, produced when the A hybrid glycosyltransferase is allowed to convert the available acceptor glycoconjugates to A without any competition from a B transferase, will sometimes escape detection in routine laboratories, especially if automated blood grouping equipment is used.

Conclusions
===========

A new hybrid, *A*^*weak*^allele with *O*^1*v*^and *A*^2^characteristics with a crossing over point in intron 5 has been found at the blood group ABO locus in five individuals of diverse Black African backgrounds. To our knowledge this is the only defined ABO subgroup allele so far associated with an African ethnic origin.

Sequencing of all seven exons of these *A*^*weak*^alleles showed two major exons (exons 6 and 7) were identical to the most frequent *A*^2^allele, although the intervening intron 6 had mutations only found so far in Black Africans. Exons 1--5 had sequences consistent with the *O*^1*v*^allele, except for two novel changes, the most important one of which (46G\>A) results in an amino acid substitution in the putative trans-membrane region of the translated protein (glycosyltransferase). The other novel change (lack of 189C\>T) led further to the identification of two new *O*alleles.

This new hybrid allele shows how mutations in early exons, far from the enzyme product\'s active site, can affect expression of the blood group A antigen on the erythrocyte surface.

Methods
=======

Blood samples and blood group serology
--------------------------------------

Blood samples from individuals living in Portugal, Sweden, Switzerland and the USA were referred to our laboratory for genomic analysis due to unclear phenotyping. Blood samples from first-degree relatives were only obtained in one case.

One hundred and thirty blood samples available at the Blood Centre, University Hospital, Lund from blood donors and other apparently healthy individuals with mixed phenotypes and mixed ethnicity (Africans, Europeans, Jordanians) were used for screening purposes. Their ABO group was determined according to current practice \[[@B30]\].

Routine *ABO*genotyping
-----------------------

All oligonucleotide primers used were synthesized by DNA Technology ApS (Aarhus, Denmark). DNA was prepared in Lund using a simple salting-out method \[[@B31]\].

The initial *ABO*genotyping comprised duplex PCR-RFLP and PCR-ASP analysis of exons 6 and 7 across intron 6 and subsequently DNA sequencing of the *ABO*gene and its regulatory elements was performed \[[@B7],[@B16],[@B19],[@B20]\].

Selected homozygous and heterozygous DNA (samples homozygous for *O*^2^and *B*allele were not available) from blood donors and other apparently healthy individuals at the reference laboratory in Lund was used for identification of introns 2 to 5 from the common alleles *A*^1^*, A*^2^*, B, O*^1^*, O*^1*v*^and *O*^2^.

PCR amplification of the *ABO*gene for DNA sequencing
-----------------------------------------------------

Primers used to amplify DNA fragments and for allele-specific direct sequencing of the seven exons and intron 6 are described elsewhere \[[@B16]\].

Alternatively, polymerase chain reaction (PCR) was carried out using Expand High Fidelity PCR system (Roche Molecular Systems, Pleasanton, CA, USA) to amplify different intron fragments and for screening for mutations 188G\>A and 46A\>G. Amplifications were performed with primer pairs as shown in Table [2](#T2){ref-type="table"}. An internal positive control primer pair was used in each PCR reaction. Amplification was performed in a reaction volume of 20 μl with 0.5 μmol/L of each primer, 2 nmol of each dNTP, and 100 ng of genomic DNA. As thermostable enzyme we used 0,5U from the Expand High Fidelity PCR System in the supplied buffer 2 with a final Mg^2+^concentration of 1.5 mM according to the manufacturer (Roche Molecular Systems). After an initial denaturation step at 95°C for 2 min followed 10 cycles of denaturation (94°C for 20 s), annealing (65°C for 45 s) and extension (72°C for 1.5 min), then 25 cycles at 94°C for 20 s, 61°C for 30 s and 72°C for 1 min and a final extension for 5 min.

###### 

Oligonucleotide primers used for PCR amplification, sequencing and screening in this study.

  Primer name      F/R\*      Nucleotide sequence (5\' → 3\')   Position          Function
  ---------------- ---------- --------------------------------- ----------------- ---------------------------------------------------------------------------------
  mo-21s           F^1--3^    GGTGAGAGAAGGAGGGTGAG              intron 1          amplification-sequencing of intron 2 for all alleles
  mo-31r           R^1,4^     CCAGCACCCCGGCCAGCA                intron 3          amplification-sequencing of intron 2 /screening of 46G\>A
  ABO-46A-F        F^4^       CCAGGAAAACCAAAATGCCACA            exon 2            screening of 46G\>A
  ABO-106G-R       R^2^       TAGACTTCTGGGGCTTAGGAC             exon 3            amplification of *O*^2^allele in intron 2
  ABO-106T-R       R^3^       AGACTTCTGGGGCTTAGGAAC             exon 3            amplification of new hybrid allele in intron 2
  ABO-inII-123F    F          GTTATCAGGGTCCTAAGGACAG            intron 2          sequencing of intron 2
  ABO-inII-660R    R          CTGCCTGTTGGTCCCTTCCTC             intron 2          sequencing of intron 2
  ABO-133s         F^5--8^    GCCCCAGAAGTCTAATGCCAG             exon 3            amplification-sequencing of introns 3 and 4
  ABO-202 cons-R   R^5^       GGGAGGCACTGACATTATACC             intron 4/exon 4   amplification-sequencing of intron 3 (except *O*^2^*, B*and hybrid alleles\*\*)
  ABO-188A-R       R^6,9^     ATACCTTGGCAACGAGACGT              intron 4/exon 4   amplification-sequencing of hybrid allele in intron 3 and screening
  ABO-220 T-R      R^7,10^    CCACGGTGTCAGCACCTTTGA             exon 5            amplification-sequencing of *O*^2^allele in introns 3 and 4
  ABO-220 C-R      R^8,11^    CACGGTGTCAGCACCTTTGG              exon 5            amplification-sequencing of *B*allele in introns 3 and 4
  ABO-inIII-F      F^9^       GCTGGCCGTTACAGGGTCTG              intron 3          screening of 188G\>A mutation in exon 4
  ABO-inIII-425F   F          GCTGCCCTCATCTCTGTGACA             intron 3          sequencing of intron 3
  ABO-inIII-672F   F          GTGCTATGGCCTCTGTTGGG              intron 3          sequencing of intron 3
  ABO-inIII 916F   F          CTCTGGCAGTTGATGCTGGC              intron 3          sequencing of intron 3
  mo-41s           F^10,11^   TAAATCCTGCTCCTAGACTAAAC           intron 3          amplification-sequencing of intron 4
  ABO-inIV 170F    F          GACTTGGCCCTCGTCCTGCA              intron 4          sequencing of intron 4
  ABO-inIV-429R    R          GACTAGCCTGGCCAACATGG              intron 4          sequencing of intron 4
  ABO-inIV-852F    F          TAGCAACTCCATTTTCCCTCCC            intron 4          sequencing of intron 4
  ABO-inIV 877R    R          GTTGGAGTAGCAGACTCATAACA           intron 4          sequencing of intron 4
  ABO-inIV 1122F   F          CTCCTGAGCCTCTACAATCCT             intron 4          sequencing of intron 4
  ABO-inIV 1411F   F          CTCTACGTCCCTCCCAGCCT              intron 4          sequencing of intron 4
  ABO-229F         F^12,13^   CTACCCCCAGCCAAAGGTGC              exon 5            amplification-sequencing of all alleles in intron 5
  ABO-297A-R       R^12^      GTTGAGGATGTCGATGTTGAAT            exon 6            amplification-sequencing of *A*^1^*, A*^2^, *O*^1^and hybrid allele in intron 5
  ABO-297G-R       R^13^      GTTGAGGATGTCGATGTTGAAC            exon 6            amplification-sequencing of *B, O*^1*v*^and *O*^2^alleles in intron 5
  mo-101s          F^4,9^     CCGTCCGCCTGCCTTGCAG               intron 6          internal control primer pair in screening
  EPB-79R          R^4,9^     TACTTGTTCAGGTGGCTCTCGTC           exon 7            internal control primer pair in screening

\* Forward/reverse primer. \*\* *O*^2^*, B*and hybrid alleles were examined in heterozygous samples. The numeral superscripts denote primer combinations. Primers with the same number were used in the same primer mixes for amplification of *ABO*gene fragments.

PCR products were excised from 3% agarose gels (Seakem, FMC Bioproducts, Rockland, ME, USA) stained with ethidium bromide (0.56 mg/l gel, Sigma Chemicals, St. Louis, MO, USA) following high-voltage electrophoresis and purified using the Qiaquick gel extraction kit (Qiagen GmbH, Hilden, Germany).

The Big Dye Terminator Cycle Sequencing kit (Applied Biosystems, Foster City, CA, USA) and an ABI PRISM 310 Genetic Analyser (Applied Biosystems) were used for direct DNA sequencing with capillary electrophoresis and automated fluorescence-based detection according to the manufacturer\'s instructions. Sequence analysis was performed with SeqEd software 1.03 (Applied Biosystems).
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Note
====

^1^Nomenclature used in the Blood Group Antigen Gene Mutation Database <http://www.bioc.aecom.yu.edu/bgmut/abo.htm>.
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